PRQR ProQR Therapeutics N.V.

NASDAQ
$1.18

ProQR Therapeutics N.V. (PRQR) is expected to report earnings on February 11, 2027, before the market open. The consensus earnings estimate is a loss of $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.6% since its last earnings release on November 12, 2026.

ProQR Therapeutics N.V. Beat Consensus Estimates
Thursday, November 12, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.13)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.31

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis, or CF.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.